汪海岩,赵利红,张敬川.rAd-p53联合化疗及局部热疗治疗恶性浆膜腔积液[J].中国肿瘤,2012,21(9):717-720. |
rAd-p53联合化疗及局部热疗治疗恶性浆膜腔积液 |
rAd-p53 Combined with Chemotherapy and Local Thermotherapy for Patients with Malignant Serosal Cavity Effusion |
投稿时间:2012-02-28 |
DOI: |
|
 |
中文关键词: 重组人p53腺病毒注射液 恶性浆膜腔积液 化疗 局部热疗 |
英文关键词:recombinant human p53 adenovirus injection malignant serosals cavity effuion chemotherapy local thermotherapy |
基金项目: |
|
摘要点击次数: 1607 |
全文下载次数: 1192 |
中文摘要: |
摘 要:[目的] 探讨浆膜腔内灌注重组人p53腺病毒注射液( rAd- p53)及顺铂联合区域热疗治疗恶性浆膜腔积液的临床疗效及毒副作用。[方法] 60例恶性浆膜腔积液患者随机分为2组,观察组30例每周腔内注射rAd-p53 2支(1×1012vp/支),72h后腔内再注入顺铂60mg,连用2周,1h后行局部热疗1h,热疗2次/周,共8次,4周后评价疗效及不良反应。对照组除不给予rAd-p53外, 腔内化疗、热疗与观察组相同。[结果] 观察组有效率( CR+ PR) 为86.7%,对照组为60.0%( P=0.01)。观察组生活质量改善率明显优于对照组(70% vs 30%,P=0.006)。观察组治疗后免疫功能未受损害。观察组不良反应主要为自限性发热。[结论] 腔内rAd-p53联合化疗及局部热疗控制恶性浆膜腔积液安全有效,疗效确切,同时可改善患者生活质量。 |
英文摘要: |
Abstract:[Purpose] To investigate the response and toxicity of intraperitoneal recombinant adenovirus p53 injection (rAd-p53) and cisplatin combined with local thermotherapy for malignant serosal cavity effusion. [Methods] Sixty cases with malignant serosal cavity effusion were randomly divided into two groups. Patients in observation group(n=30) received intracavitary administration of rAd-p53×2 (1×1012vp per piece),cisplatin 60mg 72h later intraperitoneal injection weekly for 2 weeks, then thermotherapy was operated twice a week, a total of 8 times underwent. Patients in control group (n=30) were given the same regimens as observation group except rAd-p53. [Results] The response rate (CR+PR) of observation group and control group was 86.7% and 60.0% respectively(P=0.01). The quality of life improvement rate in observation group was significantly higher than that in control group (70% vs 30%, P=0.006).The immunity of patients in observation group was unimpaired. The unique toxicity of observation group was transient fever.[Conclusion] rAd-p53 combined with chemotherapy and local thermotherapy for malignant serosal cavity effusion is safe and effective, and can improve the quality of life. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |